Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Cardonilli and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)
Cadonilimab|Clear Cell Renal Cell Carcinoma|Neoadjuvant Therapy
DRUG: Cadonilimab Combined With Lenvatinib
ORR, Objective Response Rate (ORR) based on RECIST 1.1 criteria., Evaluation at the end of Cycle 6 (each cycle is 14 days) of Cadonilimab treatment
Through the neoadjuvant treatment with a combination of Cardonilli and Lenvatinib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for nephron-sparing surgery but faced considerable difficulty in preserving the kidney (T1b with an endophytic component ≥75% or T2)